sb 239063 has been researched along with Cerebral Infarction in 1 studies
SB 239063: structure in first source
SB-239063 : A member of the class of imidazoles carrying 4-hydroxycyclohexyl, 4-fluorophenyl and 2-methoxypyrimidin-4-yl substituents at positions 1, 4 and 5 respectively.
Cerebral Infarction: The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Legos, JJ | 1 |
| Erhardt, JA | 1 |
| White, RF | 1 |
| Lenhard, SC | 1 |
| Chandra, S | 1 |
| Parsons, AA | 1 |
| Tuma, RF | 1 |
| Barone, FC | 1 |
1 other study available for sb 239063 and Cerebral Infarction
| Article | Year |
|---|---|
SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia.
Topics: Animals; Cell Death; Cerebral Infarction; Enzyme Inhibitors; Imidazoles; Ischemic Attack, Transient; | 2001 |